Background: To evaluate pathologically confirmed incidence of pseudoprogression and its impact on survival in glioblastoma multiforme (GBM) patients treated with radiotherapy and concurrent temozolomide (TMZ), followed by 6 months of TMZ maintenance therapy.
G lioblastoma multiforme (GBM) with its dismal prognosis is the most common primary brain tumor of adulthood. The results of the cooperative randomized phase 3 trial of European Organization for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada (NCIC) set the postoperative concurrent radiotherapy (RT) and temozolomide (TMZ) followed by 6 courses of maintenance TMZ as the standard of care for newly diagnosed GBM patients. 1 The results of this benchmark study and its recent update showed that the addition of concurrent and maintenance TMZ to RT was associated with a significant survival advantage at 2 and 5 years. 1, 2 Current assessment of response to treatment and disease progression, which includes the variations in the contrastenhancing tumor volume on radiologic imaging, neurologic functions, and steroid dosage is based on the criteria defined by Macdonald et al in 1990. 3 Although these cornerstone criteria serve as a useful tool for routine practice, results of recent clinical trials suggest strong doubts on potential biasing effects of TMZ as radiosensitizer and RT combination on the radiologic evaluation of disease progression. [4] [5] [6] [7] [8] [9] [10] [11] [12] The treatment-related changes in cell structure and metabolism created with this combination can lead to disruption of blood-brain barrier with the resultant observation of an early radiologic increase in contrast enhancement at magnetic resonance imaging (MRI), which may falsely mimic true progression. [13] [14] [15] [16] This phenomenon, which is indistinguishable from true tumor progression, was first described by Hoffman et al 17 in a group of malignant glioma patients treated with RT and carmustine, and is currently labeled to pseudoprogression.
Although increasingly reported, our knowledge about the true incidence of the pseudoprogression in GBM patients is limited because of scarcity of data on this newly focused condition. Absence of widely accepted distinct imaging method(s) and/or biochemical markers which may discriminate pseudoprogression from true progression further challenges its diagnosis, and therefore pathologic evaluation remains as the current most reliable tool for definitive diagnosis. However, on account of the need for avoidance of second surgery in a considerable proportion of patients because of various reasons, like the difficulties in surgery and/or medical tolerance problems, pathologic confirmation of diagnosis is not routinely reported in published series. This further hinders the determination of the true incidence of pseudoprogression and reliability of survival analysis in salvage studies. Therefore, we planned to retrospectively analyze the data of 63 consecutive patients treated according to the standard EORTC/NCIC protocol for the diagnosis of GBM. Our primary aim was to figure out the pathologically confirmed incidence of pseudoprogression and its impact on survival in this group of patients.
PATIENTS AND METHODS

Eligibility
The database maintained by the Department of Radiation Oncology, Baskent University Medical Faculty, was retrospectively searched to identify all patients with histologically confirmed GBM, who received postoperative partial brain RT with concurrent TMZ between March 2007 and February 2009. To be eligible patients, they had to meet the following inclusion criteria: age between 18 and 70 years, Karnofsky Performance Status Z70, no prior cranial irradiation, no prior chemotherapy, available contrast-enhanced preoperative and postoperative MRI scans, and adequate hematologic, renal, and hepatic functions.
The study, approved by the institutional review board of Baskent University before collection of all patient information, was conducted according to the principles of the Declaration of Helsinki and the rules of Good Clinical Practice.
Treatment
On the basis of our standard treatment policy in such patients, all patients first underwent surgery with the aim of maximal safe resection. After surgery, 3-dimensional conformal RT at a dose of 2.0 Gy per fraction once daily on 5 days a week over a period of 6 weeks to a total dose of 60 Gy was delivered by using a linear accelerator. Concurrent chemotherapy consisted of TMZ at a daily dose of 75 mg/m 2 on 7 days a week from the first until the last day of RT over 49 days. After a 4-week of break, patients received up to 6 cycles of maintenance TMZ (200 mg/m 2 /d) for 5 days every 28 days. Prophylaxis against Pneumocystis carinii with either pentamidine or trimethoprim-sulfamethoxazole was mandatory during concurrent RT and TMZ. 18 
Assessment of Response and Salvage Treatment
After completion of RT and concurrent TMZ, all eligible patients underwent gadolinium-enhanced MRI of the brain every 2 months for the first year, and every 3 months thereafter, for response assessment. More frequent MRI scanning was allowed in the case of clinical suspicion of disease progression. All patients with early radiologic progression underwent salvage surgery. With an intention to perform maximal safe resection, salvage surgery consisted of gross total excision in 11, subtotal excision in 15, and biopsy in remaining 2 patients. Pathologic evaluation of surgical material in all cases included both morphologic examination and immunohistochemical studies by using marker MIB-1. Therefore, to confirm pseudoprogression, supportive MIB-1 findings were mandatory. In case of histologically proven tumor progression, TMZ regimen was stopped and such patients underwent second-line chemotherapy and/or stereotactic radiation boost if feasible. In patients with pseudoprogression, maintenance TMZ protocol was continued up to 6 cycles.
Statistical Analysis
Primary objective of this retrospective analysis was to determine the pathologically proven incidence of pseudoprogression in patients with newly diagnosed GBM who were treated according to EORTC/NCIC protocol. 1 Our secondary objective was to analyze the impact of pseudoprogression on survival outcomes. Progression-free survival (PFS) was defined as the time interval between the initiation of RT plus concurrent TMZ and the first observation of disease progression or death from any cause excluding progressive disease. Similarly, overall survival (OS) was defined as the interval between the initiation of RT plus concurrent TMZ and the date of death or last follow-up. Intergroup comparisons between the cohorts with and without pseudoprogression were performed by using the Kaplan-Meier survival curves and log-rank test analysis. A 2-tailed P value less than 0.05 was considered significant.
RESULTS
Our institutional database search revealed 63 consecutive patients with newly diagnosed GBM treated with concurrent partial brain RT plus TMZ followed by maintenance TMZ for up to 6 cycles according to EORTC/NCIC protocol. 1 Pretreatment patient and disease characteristics were as summarized in Table 1 . All patients were eligible for response evaluation and statistical analysis. During maintenance TMZ, radiologic signs of early tumor progression defined at r6 months period from the last day of chemoradiotherapy, was prominent in 28 (44.4%) patients. Eleven (39.2%) of 28 patients also had accompanying symptoms induced by massoccupying intracranial lesion(s). On the basis of the fact that there is no specific test or imaging method which can reliably distinguish pseudoprogression from true progression, all 28 patients underwent a second surgery for tissue diagnosis and salvage purposes. Of these patients, pathologic examination confirmed true tumor progression in 16 (57.2%), and pseudoprogression with tumor necrosis in remaining 12 (42.8%) patients, which corresponds to an overall pseudoprogression rate of 19%. Although not statistically significant, comparative analysis according to symptom status revealed slightly higher incidence of pseudoprogression in symptomatic patients than the others (45.5% vs. 41.1%; P = 0.82). Median time to radiologic ± clinical presentation of pseudoprogression was 2.9 months (range: 2 to 6 mo). Further analyses revealed that, majority of cases with pseudoprogression (7 of 12; 58.3%) were presented in first 2 months of follow up after completion of the combination therapy. Remaining 41.7% cases were detected in between 2 and 6 months of follow up and were evenly distributed throughout this time period. At the time of analysis, 38 (60.3%) of 63 patients had died after a median follow-up of 19.7 months (range: 4.7 to 29.9 mo). In the whole study cohort, median PFS and OS were 12.1 months [95% confidence interval (CI), 9.1-15.1 mo] and 18.3 months (95% CI, 14.4-22.4 mo), respectively ( Fig. 1) . Comparative analysis revealed that at median 19.7 months of follow up, 8 (66.6%) of 12 patients with pseudoprogression were alive which was significantly better than 19 (37.2%) of 51 patients without pseudoprogression (P = 0.008). Similarly, compared to without cohort, patients with pseudoprogression had significantly superior median PFS and OS (Fig. 2) . Corresponding median PFS and OS for 2 cohorts were 10.0 months (95% CI, 9.1-10.9 mo) versus 17.5 months (95% CI, 9.0-26.0 mo) and 14.8 months (95% CI, 11.8-17.8 mo) versus ''not reached yet,'' respectively, favoring the cohort with pseudoprogression (P = 0.014 and 0.009, respectively). As depicted in Table 2 , PFS and OS at 1 and 2 years were also significantly superior in patients with pseudoprogression compared with those without.
DISCUSSION
The EORTC/NCIC study has clearly shown that the addition of concurrent and maintenance TMZ to standard RT protocols provide significant survival advantage in patients with newly diagnosed GBM. 1 Furthermore, recent update of this benchmark study revealed a 5-year OS rate of almost 10% that has never been reached before in this poor prognostic patients group. 2 For this patients group, the widely accepted follow-up study for assessment of tumor response to RT/TMZ combination is serial MR scanning. However, this monitoring has also led to an increased awareness that many patients with early findings of neuroradiologic progressive lesion(s) after treatment do not suffer from true tumor progression. [4] [5] [6] [7] [8] [9] [10] [11] [12] In this setting, accompanying progressive clinical signs and symptoms may also mimic tumor progression in some patients and further support the misdiagnosis of true progression. However, results of salvage surgery studies, those limited to first 6 months of postchemoradiotherapy period, showed a high incidence of pathologically confirmed pseudoprogression rather than true tumor progression. [4] [5] [6] [7] [8] [9] [10] [11] [12] Incidence of radiologic doubt of tumor progression was 44.4% in our present study, however, despite the fact that all these 28 patients had underwent salvage surgery, pathologic results confirmed true progression only in 57.2% them. Remaining 42.8%, which corresponds to 19% of overall study population, showed pathologic findings associated with treatment-related necrosis without viable tumor cells and therefore judged to have pseudoprogression. Our current 19% pseudoprogression rate is in good concordance with the majority of existing literature as summarized in Table 3 . In general, most of the earlier published studies included patients with pseudoprogression in which diagnosis was based either on pathologic and/or radiologic and clinical findings. In this setting, our study differs from most of them based on the fact that all of our cases with pseudoprogression are pathologically confirmed which may offer useful data about the true incidence of this newly defined condition in GBM patients treated according to standard EORTC/NCIC protocol.
Interval between the completion of RT/TMZ and presentation of pseudoprogression has been reported to be in the range of 1 to 10 months, with most being within 2 to 6 months. [4] [5] [6] [7] [8] [9] [10] [11] [12] In our present study, majority of the cases with pseudoprogression (58.3%) were diagnosed at first 2 months of post-TMZ/RT period with a median of 2.9 months which is in good agreement with existing literature. In a similarly designed study, after concurrent TMZ and RT, Chamberlain et al 4 reported surgically confirmed pseudoprogression in 7 of 51 (14%) patients with malignant glioma, and all were presented within 6 months after completion of treatment which is very similar with current findings presented here. In our clinical experience, despite the similarities between their timing of occurrence, pseudoprogression related with RT/TMZ is clearly a distinct phenomenon compared with early postsurgical and/ or post-irradiation MRI changes those commonly observed during the first 3 months of posttreatment period. Regarding the timing of presentation of pseudoprogression which well fits with the period when the acute and subacute effects of RT and/ or chemotherapy becomes evident normally, it is reasonable to assume pseudoprogression as a variant representation of either a continuum between the subacute radiation reaction and treatment-related necrosis, or an accelerated form of chemoradiotherapy-induced tissue necrosis. In this setting, present literature which suggests that both pseudoprogression and treatment-related necrosis do not only occur more frequently after TMZ-based chemoradiotherapy, but also develop earlier if RT is combined with chemotherapy lands support for this assumption. 4, 6 However, further pathology and immunohistochemistry-based studies are warranted to prove its validity before reaching more precise conclusions.
In this study, 42.8% of reoperated patients had no viable tumor cells in pathologic examination and therefore they experienced an unnecessary and potentially life-threatening major stress with potential psychological and physical detriments on quality-of-life measures. In their similar study, Chamberlain et al 4 demonstrated a surgically confirmed pseudoprogression rate of 46.6% which is very similar to our observations. Taken together with our present study, available surgical data suggests that almost half of the GBM patients those who were judged to be progressive after standard EORTC/NCIC protocol have pseudoprogression, and are obliged to undergo an unnecessary and potentially debilitating cranial surgery. However, absence of specific clinical signs and symptoms, and universally accepted imaging techniques and/or biochemical markers, which can precisely differentiate pseudoprogression from true progression, challenges our ability to achieve accurate diagnosis without surgical interventions. In this setting, Jefferies et al 5 suggested that a criterion for identifying pseudoprogression is the absence of correlated symptoms of disease progression, but this proposal has not been accepted worldwide because edema, which often accompanies pseudoprogression also leads to symptomatic presentation. Likewise, we also could not show any significant difference between the 2 groups (45.5% for asymptomatic vs. 41.1% for symptomatic patients; P = 0.82), suggesting no predictive role for symptom status in the discrimination of true progression from pseudoprogression. Similarly, various anatomic and metabolic imaging techniques including MR spectroscopy and positron emission tomography with various tracers have been studied but neither has been found to be uniquely powerful to identify pseudoprogression. In this setting, 2 recent studies by Gahramanov et al 19 and Tsien et al 20 reported promising results for dynamic susceptibilityweighted contrast-enhanced MRI and parametric response map with cerebral blood flow measurement studies, respectively. However, regarding the limited number of patients included in both studies (14 and 13 patients, respectively), these interesting pilot results must be interpreted with caution in absence of larger series with confirmatory results. Thus, it is unfortunate that the precise diagnosis of pseudoprogression still depends on pathologic examination of the surgical specimen. On histopathologic examination, pseudoprogression can morphologically manifest with a mixture of necrotic changes with scarce amount of viable tumor cells in between (with an unknown clinical significance), which further challenges the discrimination between the true progression and pseudoprogression. Although there is no widely accepted method for this diagnostic challenge, current evidence suggests a beneficial role of immunohistochemical studies with marker MIB-1 for the assessment of the proliferative activity in areas suspicious for tumor growth. 21 However, regarding the importance of the problem, it is evident that there is urgent need for more reliable and noninvasive radiologic techniques and biochemical markers which can accurately identify pseudoprogression, Currently available data suggests more frequent occurrence of pseudoprogression after RT/TMZ; however, its impact on survival has not been established yet. In a study of 12 patients, Fabi et al 22 reported that the 2 patients with diagnosis of pseudoprogression had the longest PFS and OS time of all patients. In a relatively larger retrospective study, Sanghera et al 10 demonstrated that patients with pseudoprogression had significantly longer median survival (124.9 wk) than either patients with true early tumor progression (36 wk) or whole study population (56.7 wk, P = 0.028). In another study, Roldan et al 8 showed that median survival was better in patients with pseudoprogression (14.5 mo) compared with those with true radiologic progression (9.1 mo, P = 0.025). The authors reported that the median survival of patients with pseudoprogression was similar to those who responded to concurrent treatment (P = 0.031). In our present series, similar with these studies, the cohort with pseudoprogression had significantly better median survival, 2-year DFS and OS compared with the cohort without pseudoprogression, and that with early true tumor progression despite salvage interventions. Taken together with the available literature, our current results suggest that pseudoprogression may be a sign of a form of accelerated tumor response which ends up with better clinical outcomes. However, future larger series specifically addressing this issue are warranted to test validity of these retrospective observations.
One important limitation of our current study is the absence of identification of the O6-methyl guanine-DNA methyl transferase (MGMT) methylation status and the categorization of the patients according to this parameter, which has recently been shown to have potential importance on incidence of pseudoprogression. 7 In their recent unique study, Brandes et al 7 retrospectively evaluated 103 patients with GBM treated according to standard EORTC/NCIC protocol. Lesion enlargement, evidenced at the first MRI in 50 of 103 patients, was subsequently classified as pseudoprogression in 32 patients (31%) and early disease progression in 18 patients. Pseudoprogression was recorded in 21 (91%) of 23 methylated-MGMT promoter and 11 (41%) of unmethylated-MGMT promoter patients (P = 0.0002). Furthermore, both the MGMT promoter status (P = 0.001) and detection of pseudoprogression (P = 0.045) were found to significantly influence survival. Although the results of this study impact the importance of MGMT promoter methylation status on incidence of pseudoprogression after TMZ chemoradiotherapy, whether this finding was indicative of a higher incidence of pseudoprogression because of a higher sensitivity to treatment remains to be established. Despite the absence of MGMT status assessment, our current results which showed better survival in the presence of pseudoprogression, is in well concordance with Brandes et al' study.
